Amylyx (AMLX) Q2 Net Loss Narrows 43%
Amylyx Pharmaceuticals (NASDAQ:AMLX), a biotechnology company focused on treatments for neurodegenerative and endocrine diseases, reported its second quarter 2025 financial results on August 7, 2025. The most notable news is that it recorded no product revenue, in line with expectations after discontinuing its commercial product early in 2024, while posting a GAAP net loss per share of ($0.46). This GAAP loss was slightly wider than the consensus estimate of ($0.44), missing by $0.02 per share. Research and development costs increased year-over-year, supporting its clinical pipeline. The quarter was defined by focused execution on advancing clinical trials and managing cash, reflecting both the opportunity of its late-stage pipeline and the risks that come with having no recurring revenue.
Source: Analyst estimates for the quarter provided by FactSet.
Amylyx Pharmaceuticals is dedicated to developing new treatments for rare and serious conditions, particularly in neurodegeneration and endocrinology. Its core pipeline includes a late-stage trial in post-bariatric hypoglycemia (PBH), ongoing studies in Wolfram syndrome and progressive supranuclear palsy (PSP), and an early-stage trial for amyotrophic lateral sclerosis (ALS).
Source Fool.com
